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Autoantibodies have been associated with human pathologies for a long time, particularly with autoimmune diseases (AIDs).
Rheumatoid factor (RF) is known since the late 1930s to be associated with rheumatoid arthritis (RA). The discovery of
anticitrullinated protein antibodies in the last century has changed this and other posttranslational modifications (PTM) relevant
to RA have since been described. Such PTM introduce neoepitopes in proteins that can generate novel autoantibody specificities.
The recent recognition of these novel specificities in RA provides a unique opportunity to understand human B-cell development in
vivo. In this paper, we will review the three of the main classes of PTMs already associated with RA: citrullination, carbamylation,
and oxidation. With the advancement of research methodologies it should be expected that other autoantibodies against PTM
proteins could be discovered in patients with autoimmune diseases.Many of such autoantibodiesmay provide significant biomarker
potential.
1. Introduction
Specificity and memory are the hallmarks of the adaptive
immune system. Immunological memory is well recognised
but still not fully understood. It was first observed in
antiquity, during the plague infection in Athens. It is also the
basis of vaccination, which was first attempted in India over
a thousand years ago when smallpox inoculation to healthy
people resulted in a milder epidemic, while protection lasted
many years, particularly in the absence of reexposure to the
antigen.Molecular immunology has nowunravelled the early
steps towards the establishment of immunological memory;
however, several areas remain unexplained particularly the
mechanism of plasma cell development and maintenance.
The recent recognition of the specificity of novel autoan-
tibodies in rheumatoid arthritis (RA) provides a unique
opportunity to understand human IgG and B-cell memory
development in vivo.
The early phases of B-cell development are well estab-
lished. Initially, naive B-cells are released in the circulation,
where they meet with their antigens, becoming activated
B-cells. At this stage several models have been proposed
and IgG can develop through different routes, in a T-cell
dependent or independentmanner. In a (classic) linearmodel
[1], maturation occurs in the presence of T-cells in a germinal
centre-like reaction (GCR); B-cells switch from secreting IgM
to secreting IgG and undergo affinity maturation. Some of
these B-cells then develop into memory B-cells and others
into long-lived plasma cells (LL-PC).These LL-PC thenmove
to a bone marrow niche where they can survive for years.
They are dependent on CXCL12 expression. In a variation of
this model, activated B-cells go through a short-live plasma
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cell (SL-PC) stage before fully maturing into LL-PC [2]. In
a third model both LL-PC and SL-PC secreting IgM and
IgG were shown to develop directly from activated B-cells,
independently of T-cell help. However this only occurs in
the presence of antigen and alternative signals provided by
innate immunity mechanisms such as direct TLR activation
of B-cells [3]. It appears that these three models may actually
coexist providing a first line of defense with rapid secretion
of antibodies. However, further T-cell mediated maturation
is necessary for a second line of defense involving long-
termmemory and LL-PC [4]. An inflamed environment such
as the synovial membrane in RA (where CXCL12 is highly
expressed in active disease [5]) is believed to provide an
alternative niche for the survival of LL-PC.
Autoantibodies have been associated with human
pathologies for a long time, particularly with autoimmune
diseases (AIDs). Organ specific AIDs involve single or
multiple autoantigens. In RA, autoantibodies have long
been associated with the disease. Rheumatoid factor (RF),
an autoantibody reacting against the Fc portion of IgG
antibodies, was identified in the late 1930s. It was the most
significant biomarker associated with RA until the discovery
of anticitrullinated protein antibodies (ACPA). More
recently, other posttranslational modifications (PTM) have
been associatedwith the generation of specific autoantibodies
that can be used as biomarkers [6–10]. While proteins are
encoded by different sequences of amino acids, there
are many ways to modify amino acids once introduced in
protein sequences. Glycosylation, citrullination,methylation,
acetylation, and ubiquitination are all types of physiological
modifications. Other modifications can occur due to
interaction with foreign substances (i.e., infections),
environmental damage (such as UV exposure or chemical
pollutants) leading to the formation of chemical adducts
on the protein. Modifications including carbamylation,
acetylation, ethylation, or methylation were sufficiently
immunogenic to produce specific antibodies to these
modified sequences of amino acids [11]. The analysis of
autoantigen specific B-cell differentiation and maintenance,
at the different stages of RA progression, provides a unique
opportunity to understand disease and study immunological
B-cell memory in vivo [12, 13].
Many AIDs are characterized by chronic inflammation,
which may play a major role when inflammation-associated
events such as chemical or enzyme-mediated modification
of protein provide a source of neoepitopes that can be
recognised by antibodies as non-self. In situations of stress
such as inflammation, all types of physiological responses
can be used in an abnormal manner. Citrullination is an
enzymatic PTM which has an important role in the normal
function of the immune system, epidermis differentiation
insulation of neurons and the plasticity of the central nervous
system [14]. Chlorination of protein occurs via the conversion
of hydrogen peroxide to reactive chlorine species, such as
HOCl, by granulocytes notably during inflammation. Other
forms of oxidation result from the formation of reactive
species of oxygen, nitrogen, and sulphur as a cellular response
to various stimulations by growth factors or cytokines [15].
Oxidation products of sugars and unsaturated lipids can also
react with proteins to cause chemical modifications. Nonen-
zymatic glycation is a naturally occurring phenomenon
leading to development of PTM of proteins, nucleic acid,
or lipids; it occurs in presence of high blood glucose but
is also associated with aging and other inflammatory or
degenerative diseases [16] such as RA [17], osteoarthritis
[18], and Alzheimer’s disease [19–21]. Carbamylation is a
nonenzymatic, irreversible PTM. Carbamylation of proteins,
lipids, peptides, and amino acids is widespread in health
in mammals and is a natural physiological phenomenon.
However excessive carbamylation will appear once proteins
are exposed to high concentrations of isocyanate derived
from the increased dissociation of urea and this alters the
function of proteins [22].
Important evidence that perturbations in protein struc-
tures introduced by PTM are important in RA was brought
by studies of collagen II (CII) for which PTM were shown
to dramatically alter immunogenicity [6, 23–25] rendering
some of them arthritogenic [26–30]. CII is the predominant
cartilage collagen and a known autoantigen [23, 31, 32]. The
human joint contains abundant CII and collagen-induced
arthritis is the common experimental animal model of RA
[33, 34].Thus, antibodies toCII should be of highest relevance
in RA [32]. Nevertheless, antinative CII antibodies occur only
in 3–27% of patients with RA [29, 35–37] and, as such, it has
been difficult to substantiate the role of autoimmunity to CII
in the pathogenesis of RA. However today autoimmunity to
PTM CII has been clearly demonstrated (cit-CII [24], ROS-
CII [6, 7, 10, 38], although specific anticarbamylated CII
remains to be demonstrated in human sera). These findings
support the possibility that chemical modification of self-
antigens, in RA in particular and in inflammation in general,
may be the cause of formation of neoepitopes leading to
autoimmunity [16, 39].
2. Anticitrullinated Protein Antibodies
(ACPA) in RA
ACPAwere originally described using different names such as
anti-keratin (AKA), antiperinuclear factor (APF) antibodies,
antifilaggrin antibodies (AFA), or anti-Sa [40]. ACPA have
been associated with human pathology [41] as well as pre-
clinical disease since the early 90s [42] later confirmed [43,
44]. The importance of these antibodies was then recognised
several years later when their presence was identified as a
specific event associated with RA [45–50].Many reports were
published; however, their relevancewas reduced to a few pub-
licationswhere appropriate controls and procedures had been
followed, particularly with respect to the ELISA assays used
to detect ACPA [51, 52]. In the early years, the use of ELISA
for individual reactivities (citrullinated filagrin or keratin) or
“first generation” commercially available ELISA kits (CCP1,
Immunoscan RA, Euro-diagnostica [53]) showed equal reac-
tivity between RA (22%), healthy control sera (27%), and all
kinds of arthritis and inflammatory diseases [49] although
clear differences in titres were observed (sensitivities 45–
64% but specificity over 90%). Later, “second-generation”
ELISAs, showed higher specificity (∼98%) and sensitivity
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(40–76% depending on disease stage) [54]; however, more
recent work also showed potential association of ACPA with
psoriatic arthritis [55], periodontitis [56], and osteoarthritis
[38]. The main difference between these tests resided in the
antigens used to detect ACPA.The diagnostic value of ACPA
were therefore established by demonstrating the importance
of using appropriate citrullinated peptide [40, 51, 57]. The
development of a highly sensitive noncommercial ELISA,
based on protein targets identified as reactive with ACPA in
synovial tissue (i.e., alpha and beta fibrinogen) was therefore
explored [58]. Importantly, positivity ofACPA for one or both
to these two citrullinated peptides covered all reactivity in RA
sera [59].
2.1. Citrullination. ACPA represent a family of autoanti-
bodies. However, only IgG-isotype of ACPA is specifically
associated with RA. The antigen which triggers the immune
reaction recognized by ACPA lies in the modification of pro-
tein (i.e., citrullination). In summary, after years of research,
it was shown that this modification converts an arginine
into a citrulline amino acid residue (citrullination) and is
performed by an enzyme, peptidylarginine deiminase (PAD),
thereby producing the immunogenic epitopes (Figure 1(a))
[60]. A consensus sequence, present in a wide range of
proteins, is required for the modification of the arginine
residue by the PAD. Metabolic stress related citrullination
has also been proposed to play a role in multiple sclerosis
[61, 62], Alzheimer’s disease [20, 21], and cancer [63, 64].The
modifications introduced by PAD enzymes have important
physiological roles, especially during differentiation, develop-
ment, and apoptosis. PAD enzymes are expressed in a wide
range of tissues (epidermis, sweat glands, hair follicles, ovary,
and testis). In the synovium, only the enzymes PAD 2 and 4
are expressed; however, their expression is not specific for RA
as they are also found in other forms of inflammatory and
noninflammatory arthritis [65]. How both intracellular and
extracellular proteins are citrullinated remains at the centre
of many debates. PAD enzymes are necessary to catalyse
protein deimination. PADs are not actively secreted in the
intercellular space, although quite a few of their targets
are extracellular proteins. Two immune-mediated membra-
nolytic pathways (mediated by perforin and the membrane
attack complex MAC), which are active in the RA joint
and of importance in RA pathogenesis, have been proposed
as possible ways by which PADs may be released in the
joint microenvironment [66]. Several human citrullinated
proteins have now been identified as target antigens of ACPA
in RA (collagen, fibrinogen, vimentin, enolase, etc.) [40,
58, 59, 67, 68]. ACPA recognise citrullinated cross-reactive
proteins but it is the presence of ACPA that is specific for RA
rather than their protein antigens.The local context in which
the proteins targeted for citrullination are expressed does not
seem to have much importance; for example, filaggrin, which
is an epithelial target of ACPA in RA, is not expressed in
synovial tissue [58].
2.2. Clinical Relevance of ACPA. In RA patients, the presence
of ACPA was associated with progressive and destructive
disease outcomes [69–71], X-rays demonstrating the presence
of erosions earlier and at a greater frequency in ACPA+
patients [72]. ACPA positivity was also associated with the
presence of RF and shared epitope (SE) [50]. Combination
analysis showed independent additive effects of these three
factors for high radiological risk [35, 50, 69, 73]. Furthermore,
the extraarticular manifestations that often determine the
severity and comorbidity of RA were also closely associated
with ACPA positivity [74]. Therefore, although disease onset
can follow a similar course, the erosive and destructive nature
of ACPA+ RA has resulted in clinicians and scientists con-
sidering the diseases as two distinct entities [75]. The main
clinical use of these antibodies is however their diagnostic
value, now recognised for over 25 years [45–50, 76] but only
more recently used as a diagnostic biomarker. Sensitivity
(∼40%) and specificity (over 95%) of ACPA as diagnostic
biomarker are now recognised in early inflammatory arthritis
patients with a suspicion of RA [54].
A study using matched serial serum samples (blood
donations) fromearly RApatientswith short disease duration
highlighted the importance of ACPA in predicting disease
severity [50, 77]. The results also showed that radiological
damage was more apparent in the groups which had been
ACPA+ even before diagnosis was achieved. Radiological
progression was also more substantial in this group after 2
years of follow-up. Importantly, these associations were not
observed with RF. In contrast, ACPA titres were reduced over
the course of disease when patients had a good response to
therapy and titres of ACPA at baseline were higher in patients
with poorer response. Taking this a step further, van Gaalen
and colleagues prospectively studied a cohort of patients at
an earlier stage of the disease in order to determine which
markers may predict disease progression and persistence
[78]. Individuals with an inflammatory arthritis but who did
not fulfill the American College of Rheumatology (ACR)
classification criteria were recruited. Multivariate analysis
confirmed ACPA as an important independent predictor
of RA with 93% developing RA within 3 years if ACPA+
at baseline. Given the clinical relevance of ACPA, it is
not surprising that the new ACR/European League Against
Rheumatism (EULAR) 2010 RA classification criteria have
includedACPA titre in order to improve the diagnosis of early
RA [79].
Studies which have evaluated ACPA titres while treating
RA are emerging with variable observations (recently
reviewed in [80]). Conventional antirheumatic drugs
(DMARDs, including methotrexate, hydroxychloroquine,
minocycline, or sulfasalazine) induce a marginal reduction
in ACPA titres (>25%) over the course of treatment in about
50% of patients and a more pronounced decrease (>50%) in
less than 30% of patients [81]. Response to TNF blockade was
associated with lower baseline titres for ACPA, other clinical
parameters being similar [82]. Response was also associated
with a sustained reduction in ACPA titres, other studies
showing similar ∼30% reduction of serum ACPA titres after
anti-TNF treatment [81–92]. However, several other reports
showed little or no effect on ACPA titre [93–97]. Therapeutic
B-cell depletion (using Rituximab an anti CD20 antibody
depleting naive, memory, and preplasma cells but not plasma
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Figure 1: (a) Enzymatic generation of citrulline from arginine catalyzed by peptidylarginine deiminase (PAD); (b) non-enzymatic formation
of homocitrulline by carbamylation of lysine by cyanate; (c) products of reactions between tyrosine with reactive oxygen species (forming
dityrosine), reactive nitrogen species (forming 3-nitrotyrosine) and reactive chlorine species forming 3-chlorotyrosine; (d) examples of AGEs
formed including carboxymethyl arginine and pentosidine (formed between an arginine and lysine residue).
cells) has marginal effect on ACPA titres [98–101] or not at
all [102]. Significant reductions of ACPA titres were only
observed in patients who responded to chemotherapy and
higher titers of ACPA were associated with lack of clinical
improvement [103].
3. Anticarbamylated Protein Antibodies
(Anti-CarPA) in RA
The first demonstration of the deleterious effects of protein
carbamylation in humans was made in the 1970s [104]. The
quantification of carbamylation-derived products (CDPs)
remains rarely used in clinical practice [105] and evaluation
of antibodies against carbamylated proteins is just emerging.
PTM through carbamylation has been implicated in vascular
dysfunction in renal disease, atherosclerotic plaque forma-
tion [106], and antibiotic resistance [107].
3.1. Chemical Reaction. Unlike citrullination which is cat-
alyzed enzymatically, carbamylation (often referred to as
homocitrullination) is a chemical modification. It can occur
ubiquitously in the presence of the reactive metabolite,
cyanate. One of the cyanate sources is the spontaneous
degradation of urea, which is constantly and ubiquitously
generated in the body and always in equilibriumwith cyanate.
Therefore, wherever there is urea, there is cyanate and the
potential for homocitrullination. However, under normal
physiological conditions, concentrations of both are too low
for any significant proteins modification.
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Theoretically, any protein can be carbamylated in vivo.
However, the susceptibility of each protein to such modifi-
cation depends on various parameters, such as the number
and accessibility of lysine and arginine amino groups, and
the protein lifespan. As carbamylation is nearly irreversible,
it is more likely to affect long-lived proteins as they may
acquire homocitrulline residues over time [9]. Various CDPs
can be formed, among them 𝛼-carbamyl-amino acids (or 𝛼-
carbamyl-proteins) when 𝛼-amino groups are involved, and
𝜀-carbamyl-lysine, also called homocitrulline, when 𝜀-amino
groups are involved (Figure 1(b)) [104]. The carbamylation
of amine groups leads to a change in the charge of the
molecule. Carbamylated derivatives may therefore acquire
biological and antigenic properties that are different from
those of the noncarbamylated molecules. On the other hand,
carbamylation-induced conformational changes in proteins
are also associated with partial or complete loss of protein
functions [26], inhibition of enzymatic activities particularly
relevant in RA such as matrix metalloproteinase-2 [108] or
tissue inhibitor of metalloproteinase-2 [109], modification of
hormonal activities (i.e., insulin [110], glucagon [111], adreno-
corticotropic hormone [112], and erythropoietin [113]), and
by affecting proteins such as haemoglobin [114], albumin
[115], and collagen [116, 117].
3.2. Clinical Relevance. Carbamylated proteins may have a
role in inflammation and as such in RA. They can modulate
the functions of inflammatory cells, as evidenced by the
inhibitory effect of carbamylated-albumin on the polymor-
phonuclear leukocyte respiratory burst [115, 118]. Carbamyla-
tion of low density lipoproteins (LDLs) by myeloperoxidase
(MPO) seems to play a pivotal role inatherosclerosis [119–
122] as well as in inflammation [106, 122–124]. Carbamy-
lated collagen stimulates the production of active matrix
metalloproteinase-9 (MMP-9) by monocytes, thus poten-
tially enhancing extracellular matrix turnover [104, 125].
Therefore it is intriguing that homocitrulline also represents
an immune target in RA.
In 2010, the presence of anti-CarPA (also called anti-
homocitrullinated protein/peptide antibodies; AHPA) was
demonstrated [26] in human sera and in an animal model
of autoimmune arthritis expanding the set of known autoan-
tibodies related to RA. Reactivity to carbamylated animal
protein has been reported but the exact nature of the autoanti-
gens recognised by anti-CarPA remains elusive. Fibrinogen
is extensively accessible to homocitrullination and there are
substantially more potential amino acid residues available for
this type of modification in this molecule compared to citrul-
lination [118]. The generation of antibodies to carbamylated
regions of fibrinogen in RA patients was confirmed [118].
The RA specificity of anti-CarPA was suggested (𝑛 = 84)
as these antibodies were not found in patients with other
inflammatory rheumatic conditions SLE (𝑛 = 37, 5% weakly
positive results) and psoriatic arthritis (𝑛 = 37, 3% weak
reactivity) or normal healthy individuals (𝑛 = 27). The
fact that some RA patients have reactivity to carbamylated
but not citrullinated fibrinogen supports the concept that
homocitrullination can generate unique structural antigens
on proteins, that is, although cross-reactivity between ACPA
and anti-CarPA was recently reported [118]. In another study
carbamylated vimentin was used to detect anti-CarPA in
RA patients [126]. Carbamylated vimentin was significantly
more reactive than carbamylated enolase which suggests
that the amino acids surrounding the modification (or even
the whole molecule) are contributing to its immunogenicity
[126]. The known association between ACPA and MHC
class II SE expression [127, 128] was very recently supported
for anti-CarPA with data showing that homocitrulline and
homocitrullinated peptide could potentially bind to the SE
[118].
Anti-CarPA IgG were found in the serum of 45% of RA
patients and IgA anti-CarPA in 43% [9]. The presence of
anti-CarPA partially overlapped with the presence of ACPA,
but most interestingly was also found in 16% of RA ACPA−
patients (30% were positive for anti-CarP IgA) [9]. The pres-
ence of anti-CarPA was detected in over 30% of such patients
when ACPA− therefore offering an alternative biomarker
to help the diagnostic of RA [9]. Furthermore, anti-CarPA
positivity was related to clinical outcome [9]. Detection of
anti-CarPA at disease presentation was predictive of a more
destructive disease course (evaluated using Sharp-van der
Heijde scores). Importantly, this was verified in both ACPA+
and ACPA− RA, notably offering a novel biomarker for
the diagnostic of RA and, furthermore, a clinically useful
prognostic biomarker for ACPA− disease.
In individuals with seropositive arthralgia (340 patients
positive for rheumatoid factor (IgM-RF) and/or ACPA+),
the prevalence of Anti-CarPA was 39% [129]. The presence
of anti-CarPA did not correlate with RF. Anti-CarPA were
associated with progression towards RA. Furthermore, estab-
lished association indicated that anti-CarPA positive arthral-
gia patients were more likely to develop RA and notably
within a shorter time frame compared to individual with only
RF and/or ACPA positivity. Such increased risk of developing
RA was maintained in double positive ACPA/anti-CarPA
arthralgia patients even after correction for ACPA. Higher
anti-CCP antibody levels were also observed in anti-CarPA
positive patients. These observations suggest that alternative
seropositivity in RA patients may each represent a different
disease entity with its own genetic/environmental contribu-
tions [129, 130].
Despite these promising initial findings, further research
is needed to clarify anti-CarPA responses and how they could
contribute to the clinical management of RA. Additional
studies using patients with a suspicion of RA as controls are
needed to determine the specificity of anti-CarPA for RA
diagnostics. Whether their presence predicts the develop-
ment of (ACPA−) RA in patients suffering from unclassified
joint complaints such as arthralgia or early signs of inflam-
matory arthritis remains to be established [9, 130]. Links
with environmental factors (smoking, alcohol intake, body
mass, hormonal status, periodontal disease, etc.) remains to
be elucidated. Despite the association with SE, other genetic
factors may be relevant. Early aggressive treatment in RA has
been shown to prevent future damage [131, 132]. The clinical
utility of a prognostic biomarker such as anti-CarPA in the
management of ACPA− patients with respect to their risk of
developing amore severe disease remains of great interest [9].
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4. Antioxidized Protein Antibodies in RA
Oxidative stress is a term that is used to describe situations
in which an organism’s production of oxidants exceeds the
capacity to neutralize them. The consequences are damages
to cell membranes, lipids, nucleic acids, proteins, and con-
stituents of the extracellularmatrix such as proteoglycans and
collagens. Several lines of evidence suggest a role for oxidative
stress in the pathogenesis of RA [133–139]. Epidemiologic
studies have shown an inverse association between dietary
intake of antioxidants and RA incidence [140–143], and,
reciprocally, an inverse association between antioxidant levels
and inflammation [39, 144, 145]. Reactive oxygen species
(ROS) are chemically reactive molecules containing oxygen
(such as superoxide and peroxides), and a natural byproduct
of the normal metabolism of oxygen. ROS are able to
oxidize various amino acids, according to their oxidation
potential. They have important physiological roles in cell
signaling, apoptosis, ion transport systems, wound healing
and bloodhomeostasis, and also the induction of host defense
(respiratory burst), genes, and inflammatory responses.They
can also be detrimental in situations of stress when their
levels dramatically increase to the point of harming cells.This
notably occurs when antioxidants normally protecting cells
(superoxide dismutases, catalases, peroxidases, peroxiredox-
ins, and others) are unable to manage the amount of ROS
produced [146].
Oxidative modifications by ROS are attractive candidates
as instigators of autoimmunity and this might involve a
process of “oxidative PTM intolerance” [10], resulting in a
primary B-cell response against the posttranslationally mod-
ified self-antigen [10]. Oxidative stress-induced antibodies to
carbonyl-modified protein have also been found to correlate
with severity of chronic obstructive pulmonary disease [147]
and SLE [148].
4.1. Chemical Reaction. Oxidative stress occurs during in-
flammation and causes proteins to become damaged by reac-
tive species such as reactive oxygen, nitrogen, and chlorine
species. NADPH oxidase is a major source of ROS in arthritic
joints. This enzyme reduces O
2
generating large amounts
of superoxide radical anion ∙O
2
−, which is considered the
primary ROS and may be further reduced to H
2
O
2
, which
in turn can be converted into highly reactive ∙OH or react
with Cl− to generate HOCl (in a reaction catalyzed by the
enzyme myeloperoxidase). iNOS also generates ∙NO which
is converted to ONOO− by reacting with O∙−
2
[149, 150]. In
addition, under conditions of oxidative stress, species such
as peroxynitrite (ONOO−) may be generated resulting in
nitration of tyrosine residues to form 3-nitrotyrosine (3-NT)
(Figure 1(c)) [138, 151, 152]. Indeed, antibodies recognizing 3-
NT have been identified in the synovium of RA patients and
correlate with disease activity [152].
In addition, these reactive species generate “secondary”
reactive species such as lipid peroxidation products.
Nonenzymatic oxidation by sugars can react directly or
generate reactive products such as glyoxal andmethylglyoxal;
these reactive carbonyls are capable of undergoing Maillard
reactions, first forming a Schiff base with the amine group
of amino acids, such as lysine or arginine. This intermediate
can then undergo an Amadori rearrangement to form stable
advance glycation end product (AGE) such as carboxymethyl
arginine or initiate peptide cross-linking to form pentosidine
(Figure 1(d)) [153]. The presence of these PTM on protein
increases as well as modifies their natural antigenicity and
antibodies against the native and modified forms of these
proteins are usually noncross-reacting and were detected in
RA despite the absence of hyperglycemia [17, 154]. AGEs can
have damaging effects on collagens by forming irreversible
cross-links between the fibers in the triple helix [155–158].
Another potential reaction is chlorination of aromatic
amino acids, in particular tyrosine residues, including
3-chlorotyrosine, within the polypeptide backbone
(Figure 1(c)) [159]. Under conditions of oxidative stress,
species such as peroxynitrite (ONOO−) may be generated
resulting in nitration of tyrosine residues to form 3-
nitrotyrosine (3-NT) (Figure 1(c)) [138, 151, 152]. Indeed,
antibodies recognizing 3-NT have been identified in the
synovium of RA patients and correlate with disease activity
[152]. Exposure of collagens to peroxynitrite results in
nitration of tyrosine residues and formation of posttrans-
lationally modified nitrotyrosine. These compounds
are negatively charged and further disrupt the collagen
structure. ROS levels are increased in autoimmune diseases
such as RA and SLE. The overproduction of ROS may
exceed the capacity for radical scavenging by antioxidant
enzymes or small inhibitors. Exposure of proteins, nucleic
acids, or cell membrane and free lipids to ROS modifies
amino acids creating PTM proteins and lipids by initiation
of peroxidation. There is no recognized specificity to the
protein that can be modified and oxidation depends on
steric and stochastic factors; however, enrichment for amino
acid motif YXXK in the vicinity of chlorination has been
observed [160]. Oxidized proteins identified in RA include
collagens I, II, IX, and XI, proteoglycans, and hyaluronan.
Increased oxidation of lipids is also a known feature of RA,
with the appearance of foam cell-like structures within the
rheumatoid synovium [39, 136, 161].
In the context of RA, immunoglobulins themselves can
undergo glycation to generate AGE-IgG. Autoantibodies
to such modified-IgG were also shown to be specifically
associated with RA, whereas the actual formation of AGE-
IgG was directly related to the intensity of the inflammatory
response but was not specific to RA [162–164]. Similarly,
modification of IgG by HOCl or peroxynitrite can induce a
T-cell response against IgG HOCl and peroxynitrite in RA
[165].
4.2. Clinical Relevance. The key ROS present in inflamed
joints are superoxide radical (O
2
∙−), hydrogen peroxide
(H
2
O
2
), hydroxyl radical (∙OH), hypochlorous acid (HOCl),
nitric oxide (∙NO), and peroxynitrite (ONOO−), which are
involved in acute and chronic inflammation [6, 15]. Such
ROS have been identified in synovial fluid of 90% of patients
with RA, with a shift in the oxidant/antioxidant balance in
favour of lipid peroxidation, which lead to the tissue damage
observed in joints [166, 167].
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Exposing CII to conditions which simulated those found
in an inflamed joint, resulted in chemical modifications of
native CII [6]. CII treated with hydroxyl radical (∙OH-CII),
hypochlorous acid (HOCl-CII), and peroxynitrite (ONOO−-
CII) demonstrated positivity for binding to autoantibody
specifically recognizing these various CII-modified forms in
sera from 93 of early RA patients in addition to glycation
of CII (Gly-CII) carried out with ribose. No cross-reactivity
with native CII was observed but reactivity to native CII was
seen in <20% of sera [6]. Moreover, no anti-ROS-CII reactiv-
ity was detected in other inflammatory arthritis conditions
(including psoriatic arthritis, SLE, ankylosing spondylitis,
palindromic arthritis, scleroderma, Behc¸et’s disease, primary
Sjo¨gren’s syndrome, fibromyalgia, tendonitis and reactive
arthritis [6].
In 2005 we showed that CII post-translationally modified
by ROS (ROS-CII), present in the inflamed joints, is an auto-
antigen in RA [6]. In addition, cartilage damage as a result
of collagen oxidation by glycation and formation of AGE-CII
are evident despite the absence of hyperglycemia [168].
We have recently measured auto-reactivity to ROS-CII in
synovial fluid (SF) and serum samples taken from various
phases of RA [38] and demonstrated that anti ROS-CII
reactivity is not related to markers of inflammation such as
CRP and ACPA and has potential to serve as biomarker for
several purposes. We observed high anti-ROS-CII reactivity
in DMARD na¨ıve early RA regardless of whether patients
were ACPA+ or ACPA− and with no correlation with DAS28.
The sensitivity and specificity of the binding of autoantibodies
to ROS-CII in early RA compared with healthy controls
(HC) was 92% and 98%, respectively. ROS-CII reactivity was
lower in RA patients having received their first DMARDs
treatment and achieving a good response. We also showed
that anti-ROS-CII reactivity considerably vary over time in
a mixed cohort of RA patients with established disease on
several type of treatment [38]. This was in contrast to levels
of ACPAwhich did not. We could not directly associate these
changes with DAS28, however, patients in this cohort all had
(very) active disease and it was impossible to fully ascertain
longitudinal variation between active/remitting diseases.
Further pilot data showed that in a small cohort of
ACPA+ arthralgia patients with no synovitis, only those
within a few weeks (∼12) of developing clinical evidence
of synovitis were positive for anti-ROS-CII reactivity while
those who developed symptoms after a much longer delay
were negative. Interestingly, in a study conducted in type 1
diabetes, a condition associated with RA [169], anti-ROS-CII
reactivity was restricted to SE-containing DRB1∗04 alleles
(OR 3.62; 95%CI 1.12–11.74), known to confer the greatest risk
for developing RA. Further work needs to establish whether
patients with inflammatory synovitis but not yet RA (i.e.,
undifferentiated arthritis) would be positive however, 93%
of early RA were, which altogether, strongly suggest a direct
association with the development of synovitis, hence offer a
measurable biomarker of disease development alongside the
RA continuum [38].
Anti-TNF treatment showed reduction in oxidative stress,
and these correlated with an improvement in disease activity
[170–173]. However studies evaluating changes in anti-ROS
autoantibody levels after RA anti-TNF treatment are still
missing. Our own data however suggest variation [38] which
will need to be confirmed before any biomarker value can be
confirmed.
In addition to CII, studies of RA synovial fluid and tissue
have demonstrated oxidative damage to hyaluronic acid
[174], lipid peroxidation products [175, 176], oxidized low-
density lipoproteins (ox-LDL) [136], and increased carbonyl
groups reflective of oxidation of other proteins [136, 162, 177–
179]. Evidence of oxidative damage to cartilage, extracellular
collagen, and intracellular DNA has also been demonstrated.
Protein chlorination occurs in RA at the disease site (i.e.,
synovial fluid and tissue) [159, 180] and it was proposed
that this could be the link between arthritic inflamma-
tory reactions and the initiation of autoimmune antibody
responses. The risk associated with ox-LDL in RA is mostly
related to cardiovascular risk hence not specific to RA. Ox-
LDL are strong autoantigens, essential to the development
and progression of the plaque in atherosclerosis as LDL
molecules only become immunogenic due to the oxidative
modification during early atherogenesis [181, 182]. Anti-
oxLDL antibodies are extensively prevalent in patients with
autoimmune diseases, including RA [183], SLE [184, 185],
and antiphospholipid syndrome (APS) [186, 187], diabetes
mellitus [188, 189], uremia [190]. Anti-ox-LDL antibodies
bind ox-LDL and generate immune complexes. Circulating
immune complexes are not in themselves harmful. They
cause damage only if they are deposited in tissues (notably
in the endothelium), resulting in inflammation [191, 192]. T-
cells, primarily CD4+ cells, have been found associated with
these immune complex depositions [193–196]. Cardiolipin is
also the target of oxidation (ox-CL). Anti-ox-CL antibodies
are frequent in APS patients [197, 198] due to formation of
neoepitope on cardiolipid, possibly with cross-reactivity with
anti-oxLDL antibodies notably in patients with SLE [197, 199,
200].
Finally, autoantibodies targeting AGE-modified IgG are
also present in serum of RA patients [154, 201]. Autoantibod-
ies against AGE-IgGmight be helpful in monitoring progress
in the RA disease continuum and in combination with other
clinical features of the RA might be a useful diagnostic tool
[201].
5. Animal Model Testing of PTM-Targets and
Antibody to PTM-Proteins
An important discovery in the association between anti
PTM-protein and RA was the demonstration that these
antibodies and their targets are both arthritogenic in animal
models. The citrullinated forms of collagen II appeared
more arthritogenic in rats than native collagen II [202, 203].
Within the human synovium, the immune reaction between
citrullinated fibrin and ACPA results in the activation of
effector mechanisms. Immune-complex containing ACPA
and CII citrullinated peptide can activate bloodmacrophages
via FcR resulting in the production of TNF-alpha in mice
[204, 205]. A similar response by synovial macrophage would
promote local inflammation which in turn will favour plasma
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extravasation and fibrinogen polymerisation. These deposits
then could get citrullinated by locally expressed PAD and
therefore become new target for ACPA closing the circle
for self-perpetuation. PAD 2 and 4 are expressed in the RA
synovium (and in other inflamed tissues) but importantly
in correlation with the intensity of inflammation [65]. The
arthritogenicity of chlorinated-CII versus native CII (Cl-
CII) was also demonstrated in a rat strain [159, 206, 207].
This might be caused by an increased immunogenicity of
Cl-CII, resulting in a stronger antibody-inducing capacity.
Hydroxyl radical modification of collagen type II (OH-CII)
also increases its arthritogenicity and immunogenicity and
resulted in an early and more severe arthritis compared to
native CII [208].
Anti-CarPA are now extensively studied to clarify
whether they are directly involved in the pathogenesis of
RA. carLDL induce an IgG response in LDL-R−/− mice and
autoantibodies also bind to humans plasma proteins [209].
The immunogenicity and an arthritogenic role of the anti-
homocitrulline immune responses were confirmed using
animal model of arthritis. Immunization of several mouse
lines (NMRI, BALB/c, and C57bl/6) with carbamylated-
peptides leaded to a Tcell dependent activation of B-cell and
the production of autoantibody [26]. Direct intra-articular
injection of the carbamylated-peptides in these mice induced
a severe erosive arthritis [26]. This study was also the first to
report the presence of anti-CarPA in RA patients, both in the
joints and circulation, and importantly in relation to erosions.
Rabbits immunized with carbamylated-proteins resulted in
high-affinity antibodies to homocitrulline-containing colla-
gen telopeptides and to less strong anticitrulline-containing
telopeptides and mutated citrullinated vimentin [27].
The exact pathogenic potential of anti-CarPA therefore
appears to be similar to that of ACPA [210].The possibility of
cross-reactivity between these two antibody types demands
further investigation into the identification of true targets in
RA. If antibody responses to citrulline and homocitrulline
are indeed arthritogenic, important questions remain: which
antibodies are pathogenic? Is it the specificity of the target
antigen, the quantity, and diversity of the response, and/or
merely the binding affinity to available targets in the arthritic
joint, which are important in determining arthritogenicity
and clinical disease progression [211]?
6. Autoantibodies and B-Cell
Development in RA
To date the overall development of the anti-PTM-protein
antibody producing B-cell clones remains poorly understood.
ACPA of the IgG are the immunoglobulin isotype specifically
associated with RA [57]. This suggests that an immune
reaction leading to the development of IgG ACPA is taking
place at some point before the onset of RA. ACPA of the
IgG subclasses 1 to 4, are detected; however a major bias is
observed towards an IgG1 (86% alone) and IgG4 but with
a very limited involvement of IgG2 and 3 [57]. Such bias
correlates closely with an imbalance toward Th1 polarisation
which is well described in RA.
The presence of B-cell reactivity to Cl-CII in RA patients
was established [6, 38]. Spontaneous production of ACPA
could only be obtained fromB-cells isolated from the synovial
fluid and bone marrow of IgG ACPA+ RA patients. The
presence of IgG ACPA up to 15 years before symptoms has
also been reported [44, 212]. A cross-sectional study also
reported that titres of IgG ACPA appeared higher shortly
before the onset of RA suggesting reactivation of the produc-
ing B-cells [44]. Finally, the strongest argument in favour of
this immune reaction is the T-cell response to citrullinated
peptide observed in RA patients but not in healthy controls
[213, 214].
The hypothesis that each stage of the disease represents
an evolution in ACPA specific B-cell maturation is therefore
attractive. At this stage, however, it has not yet been either
demonstrated or nullified. ACPA have been shown to be
present at detectable levels years before the firstmanifestation
of RA with high risk for these individuals to develop RA
within 5 years [22, 124]. In the preclinical phase (ACPA
positivity but no disease symptoms), ACPA-IgG circulate
(sometimes for many years) suggesting that, at least, isotype-
switched ACPA-specific B-cells are present. During this
disease initiation phase, cross-sectional analysis also showed
that ACPA titres are higher just before onset of symptoms
[215–217].
In vivo, differences in ACPA levels [73], fine specificity
or epitope spreading [218, 219], avidity [220–222], isotype
usage [223], and glycosylation [224] may be associated with
differences in the potential to activate effector mechanisms,
thereby influencing their biological potency [220]. Epitope
spreading is often a hallmark of progressive B-cell responses
and was described for ACPA and was associated with an
increase and/or shift in antigen recognition during the course
of an autoimmune response [218, 225, 226]. Fine mapping
analysis of preclinical sera compared to early and established
RA showed subtle difference in either the identity or the
numbers of epitope detected between the different phases of
the disease [43, 215, 216, 227, 228]. Our own unpublished
data using the same platform showed a particular epitope
detected exclusively in synovial fluid which may represent a
unique specificity with local retention of the ACPA (as not
detected in sera) suggesting local B-cell reactivity. Despite
the association between the presence of anti-CarPA and
the broadening of ACPA’s fine specificities, anti-CarPA are
generated independently of ACPA and, to date, are largely
noncross-reactive although the panel of currently available
carbamylated antigens remains limited. The effect of anti-
CarPA in arthralgia patients is notably independent of the
effect of ACPA (after correction) [129]. It will be of great
interest to expand the investigation for anti-CarPA and anti-
ROS specificities, particularly among ACPA− patients and
determine whether these antibodies could have pathological
effects in RA patients [229].
A few studies already have shown that circulating ACPA-
IgG differ in avidity but still relatively little is known about
avidity maturation of ACPA before and during the RA con-
tinuum [220]. Lower ACPA avidity was reported in ACPA+
asymptomatic individuals compared to avidity in ACPA+
patients with joint symptoms (arthralgia), which was similar
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to avidity observed in established RA patients [221, 222].
Following immunoablative therapy, ACPA-IgG of low avidity
developed again which suggested a newly generated autoim-
mune response [103]. However, the development of high
avidity ACPA-IgG remains speculative and their presence
may be only characteristic for specific RA patients, refractory,
or less responsive to immunosuppressive treatment [103]. As
mentioned previously, all immunoglobulin isotypes (IgM,
IgA, and IgE ACPA) contribute to overall ACPA activity in
RA serum [223, 230, 231]. Although autoantibodies of IgG
isotype are generally the most relevant, other studies have
shown that IgA were also specific for RA [231, 232]. IgG
are associated with radiographic progression in RA [73, 77],
but patients positive for IgA-ACPA with recent onset RA
were reported to suffer a more severe disease course over
the first three years [233] and the higher the number of
different isotypes, the greater long-term radiographic joint
damage at 5-year follow-up [234]. This data suggests that the
development of the anti-CCP isotype repertoire occurs early
in the course of arthritis [217, 235].
Glycosylation of the Fc-part of antibodies affects their
function with either a pro- or an anti-inflammatory outcome
functionality [236]. The glycosylation profile of ACPA in RA
is characterised by a low content of galactose (hypoglyco-
sylation) and sialic acid residues [224]. Hypoglycosylation
of ACPA was more pronounced than that of total IgG1,
resulting in a proinflammatory Fc-glycosylation pattern of
ACPA that could be one mechanism driving inflammation in
RA [224, 237]. Fc-glycosylation of ACPA showed significant
differences between SF and serum and, in contrast to ACPA
in serum, ACPA isolated from SF were found to be highly
agalactosylated [224]. IgG glycosylation showed association
with RA activity [238]; however, this pattern was not useful
to predict clinical response to MTX and anti-TNF treatment
in RA [239]. Finally, the specific ACPA-Fc hypoglycosylation
was detected already 6 months prior to RA onset [237].
TNF-alpha is an important factor in GCR. If disease
initiation was to coincide with a time when B-cells are
undergoing early TNF/GCR dependent maturation phases,
TNF-blockade in early disease should result in definite ACPA
titre reduction. Studies of the effect of TNF blockade in early
disease are still lacking and are in progress. In established
disease TNF-blockade is clinically efficient but may not be
able to interfere with the course of B-cell differentiation
anymore; hence studies analysis ACPA titres over the course
of anti-TNF therapy in established disease showed variable
results. In long lasting RA, B-cell ablation does not result
in major ACPA titres reduction in contrast to total IgM
titres (but not IgA and IgG) [98–102]. Plasma cells not being
directly depleted by the therapy due to the fact that they
do not express CD20, suggesting that, in established RA,
ACPA-LL-PC are present. The small reduction in ACPA
titres reported after B-cell depleting therapy (< than 20–30%)
nevertheless suggests that a small pool of ACPA producing
cells (memory and SL-PC) are affected by the therapy [240]
notably as SL-PC were evidenced in the synovium of RA
patients and were shown to secrete autoantibodies including
ACPA [241, 242].
The direct analysis of ACPA producing B-cells has proven
difficult. The classic molecular tools used to label antigen-
specific B-cells have not been very successful to date in iso-
lating ACPA-B-cells (MHC-tetramers, biotinylated-peptide
specific for ACPA BCR). ACPA-specific T-cell clones were
detected in established disease [213]. However, it remains to
be determined whether they play a role in anticitrullination
response in RA and most importantly when. The further
elucidation of the B-cell maturation path will require serial
samples from preclinical stages, then early and fully estab-
lished disease and the examination of somatic hypermutation
and affinity maturation.
Data generated to date therefore establish the presence
of an immune reaction resulting in the secretion of ACPA.
Yet, the primary stimulus leading to such production remains
unknown. An environmental association between the pres-
ence of ACPA and smoking has been established [219, 243],
and smoking is the most recognised environmental factor
reproducibly associated with RA. Recently, silica exposure
has also been linked to RA [244–246] and other immuno-
logically mediated diseases [247]. A study looking at the
link between genetics and environmental factors has shown
that the presence of ACPA was associated with the shared
epitope HLA-DRB1 in a dose dependent manner but that
smoking was only important in patients positive for ACPA
secretion [75, 248, 249]. This observation may suggest that
physiological processes associated with smoking have a role
in the initial generation of ACPA.Amodel has been proposed
in which smoking (and other agents) triggers the production
of IgG ACPA [250]. A second event leads to the citrullination
of synovial proteins which would direct ACPA immunity
towards the joints [218]. The disease would then be initiated,
and, if uncontrolled, become chronic. The role of ACPA in
the self-maintenance of RA, once it is established, is a more
easily understandablemodel; however, the exact nature of the
citrullinated protein target of ACPA remains elusive.
Therapeutic B-cell depletion results in disease improve-
ment (by 6 to 10 weeks) but not in ACPA serum titres
reduction. Synovial depletion of B-cells however is delayed
(26 to 30 weeks) probably accounting for the time necessary
to eliminate short-live plasma cells from the tissue [98].
Therefore some of the benefit of the therapy must be related
directly to the removal of B-cell (not plasma cells) from
the tissue. There has been speculation that synovial B-cells
in RA may have some unusual lack of responsiveness abol-
ishing their proliferative capability (anergic B-cells) leaving
intact their antibody production [251]. Two-way interaction
between B-cells and T-cells may be a great relevance here: B-
cells provide signals to T-cells through antigen presentation
and T-cells provide “help” to B-cells through the delivery
of cytokines and cell mediated stimulation, creating a self-
sustained feedback loop. Whether B-cells stimulate T-cells to
stimulate B-cells, vice versa or, more simply, which cell makes
the initial mistake and trigger autoimmunity has been a point
of debate for years [252]. In favor of B-cell, an argument has
been put forward for CD4+ T-cell activation being dependent
on B-cells in the synovium, in the context of a GCR and
in a HLA-DRBI restricted manner where the antigen is
harbored by the B-cells [253]. Breaking this loop should, in
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itself, restore self-tolerance. Therefore, the removal of ACPA
secreting B-cell may be more relevant to reestablishing self-
tolerance in RA as it may remove ACPA themselves but also
the source of activation for the two-way interaction between
B- and T-cells.
7. Conclusion
The findings presented in this review support the hypothesis
that PTM of self-antigens, in RA and in inflammation in
general, are a cause of the formation of neoepitopes giving
rise to autoantibodies. Whether the breakdown of tolerance
occurs because antibodies against modified self-protein are
promiscuous and bind both the modified and unmodified
self-antigen or whether they are truly specific for modified
proteins is unclear. Nevertheless, these processes contribute
to the vicious circle of chronicity by providing novel immune
reactivity, resulting in further stimulation of the immune
response against self-antigens. With the advancement of
research methodology it should be expected that novel
specificities of autoantibodies against PTM proteins could be
discovered in patients with autoimmune diseases. Many of
these autoantibodies could have significant biomarker poten-
tial. Clearly, animal models suggested therapeutic advantages
in preventing the generation or binding of potentially patho-
logical autoantibodies to the extracellularmatrix collagen and
collagen-like structures. B-cell responses to native CII have
long been known in RA but, as PTM-CII reactivity induces
or worsens experimental arthritis, it is possible that blocking
PTMcould ameliorate arthritis [7, 206]. As such, antioxidants
and inhibitors of oxidative enzymes have already been shown
to ameliorate arthritis in animal models [254, 255]. The
translation of antioxidant therapies to human clinical studies
has produced disappointing results, but targeted approaches
using novel inhibitors of oxidative enzymes offer new hope
for the treatment of RA.
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